Vector Development

Long-Term Gene Delivery Using Lentiviral Vectors Reported

Published in Cancer Weekly, November 24th, 1997

Cell Genesys, Inc., Foster City, California, announced that company collaborators at The Salk Institute have achieved successful long-term gene delivery to liver and muscle tissues using second generation lentiviral vectors.

The data demonstrate that following a single injection, gene expression was detected for at least six months and potentially indefinitely. These preclinical studies were described in the November 1997 issue of the journal Nature Genetics.

Cell Genesys is the exclusive worldwide licensee of the lentiviral gene delivery technology which was developed at The Salk Institute by Inder Verma, Ph.D. and colleagues. Company scientists,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-11-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry